

Supporting Information for

Conventional and Unconventional Alkyne Activations by Ru and Os for Unprecedented Dimetalated Quinolizine Complexes

Chi-Fung Yeung,^{a,b,†} Lai-Hon Chung,^{a,†} Sheung-Ying Tse,^a Hau-Lam Shek,^a Man-Kit Tse,^a Shek-Man Yiu,^a and Chun-Yuen Wong^{a,b,*}

^a. Department of Chemistry, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR.

^b. State Key Laboratory of Millimeter Waves, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong SAR.

†These authors contributed equally.

E-mail: acywong@cityu.edu.hk

Table of Contents

	Page
General Procedures (with synthetic procedures for all complexes)	S3
X-Ray Crystallography	S7
References	S10

General Procedures for Synthesis and Characterizations

All reactions were performed under an argon atmosphere using standard Schlenk techniques unless otherwise stated. All reagents were used as received, and solvents for reactions were purified by a PureSolv MD5 solvent purification system. *cis*-[M(dppm)₂Cl₂] and *cis*-[M(bpy)₂Cl₂] (M = Ru, Os; dppm = 1,1-bis(diphenylphosphino)methane; bpy = 2,2'-bipyridine) were prepared in accordance with literature methods.¹ ¹H, ¹H{³¹P}, ³¹P{¹H}, ¹³C{¹H}, ¹H-¹H COSY, ¹H-¹H NOESY, ¹H-¹³C HSQC, ¹H-³¹P HMBC and ¹H-¹³C HMBC NMR spectra were recorded on Bruker 600 AVANCE III FT-NMR spectrometer. Peak positions were calibrated with solvent residue peaks as internal standard. The ³¹P{¹H} NMR spectra were referenced to external P(C₆H₅)₃ (-4.7 ppm).² Labeling scheme for H and C atoms in the NMR assignments is shown in Figure S1. Electrospray mass spectrometry was performed on a PE-SCIEX API 3200 triple quadrupole mass spectrometer. Elemental analyses were done on an Elementar Vario Micro Cube carbon-hydrogen-nitrogen elemental microanalyzer.




Figure S1. Labeling scheme for H and C atoms in this work.

Synthesis of **L1** and **L2**

This ligand was synthesized according to a modified literature procedure:³ To a solution of the 2-methylpyridine/6-bromo-2-methylpyridine (1.32 mmol) in THF (20 mL) at -78°C was added lithium diisopropylamide (1.32 mL of a 2.0 M solution in THF/Hexane, 2.64 mmol) in dropwise manner. The reaction mixture was stirred for 30 min at -78°C. Then 1-phenyl-2-propyn-1-one (1.32 mmol) in THF (10 mL) was added dropwisely to the reaction mixture at -78°C and stirred for 30 min. Upon warming up to room temperature, a saturated aqueous NH₄Cl solution (5 mL) was added to the reaction mixture, the aqueous layer was extracted with Et₂O (50 mL × 2) and CH₂Cl₂ (50 mL × 2). The organic phases were combined, washed with brine (50 mL × 2), dried over anhydrous MgSO₄, and concentrated to obtain a brown oil. **L1/L2** was obtained as yellow oil after silica gel column chromatography (hexane/EtOAc: 4:1 to 7:3 (v/v)).

Synthesis of **1q(OTf)**, **1f(OTf)₂**, **2q(OTf)**, and **2f(OTf)₂**

Method 1: A mixture of **L1** (0.45 mmol) and *cis*-[M(dppm)₂Cl₂] (M = Ru/Os, 0.15 mmol) were refluxed in MeOH (50 mL) under argon for 16 hr, during which the metal precursors gradually dissolved and the color of the reaction mixture changed from pale brown to yellowish brown. Upon cooling to room temperature, saturated aqueous NaOTf solution (5 mL) was added into the reaction mixture. The volume of the reaction mixture was concentrated to about 5 mL by reduced pressure, and the resultant brown solids were collected by suction filtration, washed with deionized water (5 mL × 3), EtOH/Et₂O (10 mL × 3), and finally Et₂O (10 mL × 3). The crude product was further purified by basic alumina column and the yellow band (**1q** and **2q**) was eluted with CH₂Cl₂/(CH₃)₂CO 8:2 (v/v) mixture, while the red band (**1f** and **2f**) was eluted with 100% (CH₃)₂CO. The collected two bands were concentrated to about 5 mL and added into Et₂O (150 mL) separately to give yellow (**1q** and **2q**) and red (**1f** and **2f**) precipitates. Analytically pure bright yellow (**1q** and **2q**) and deep red (**1f** and **2f**) crystals were obtained by recrystallization of the precipitates (via layering of *n*-hexane onto a CH₂Cl₂ solution of the complexes). Reaction yields provided below are all obtained from Method 1.

Method 2: A mixture of **L1** (0.45 mmol), *cis*-[M(dppm)₂Cl₂] (M = Ru/Os, 0.15 mmol) and 20 equivalent of NaOTf were stirred at room temperature or heat at 40°C/80°C in CH₂Cl₂ (40 mL) under argon for 16 hr, during which the color of the reaction mixture changed from brown to reddish brown. Upon cooling to room temperature, the mixture was filtered and concentrated to about 2 mL by reduced pressure. The crude product was purified by column chromatography as mentioned in the last part of Method 1.

Remark: Two stereoisomers were observed for **1f** and **2f** from both NMR spectroscopy and X-ray crystallography (illustrated in Figure S2).




Figure S2. The two stereoisomers observed in **1f** and **2f**.

Synthesis of **2v**(OTf)

A mixture of **L2** (0.45 mmol), *cis*-[Os(dppm)₂Cl₂] (0.15 mmol) and 20 equivalent of NaOTf were stirred at 40°C (40 mL) under argon for 16 hr, during which the color of the reaction mixture changed from pale yellow to orange red. Upon cooling to room temperature, the mixture was filtered and concentrated to about 2 mL by reduced pressure. The concentrated solution was then added into Et₂O (150 mL) and bright orange solids were collected by suction filtration. Analytically pure bright red crystals were obtained by recrystallization of the precipitates (via layering of *n*-hexane onto a CH₂Cl₂ solution of the complexes).

Remark: The NMR spectra for **2v** suggest that the reaction product is a mixture of isomers where the two dppm auxiliary ligands can be *cis*- and *trans*- to each other, and the alkene moiety on the vinylidene ligand can have *E*- and *Z*-configurations; only the signals from the 2 major species, *E*- & *Z*-form in *cis*-configuration, are clear enough for NMR assignment.

Synthesis of **3**(OTf)

The preparation steps are same as the method 1 for synthesis of **1** and **2**, except for the column chromatography which the crude product was purified by basic alumina column and the purple band was eluted with CH₂Cl₂/(CH₃)₂CO 8:2 to 7:3 (v/v) mixture. The collected band was concentrated to about 5 mL and added to Et₂O (150 mL) separately to give purple precipitates. Analytically pure deep purple crystals were obtained by recrystallization of the precipitates (via layering of *n*-hexane onto a CH₂Cl₂ solution of the complexes).

Synthesis of **Q**(OTf)

A mixture of **L1** (0.45 mmol) and 20 equivalent of CF₃SO₃H were refluxed in MeOH (50 mL) under argon for 16 hr, during which the colour of the reaction mixture changed from yellow to very pale yellow. Upon cooling to room temperature, the solution was removed by rotary evaporator. The remained solids were dissolved by minimum amount of CH₂Cl₂ solution for recrystallization (via layering of *n*-hexane onto a CH₂Cl₂ solution of the compounds) to obtain colourless crystals. The NMR spectra of **Q** obtained from the above synthetic methods are identical to the previous reported data.^[4] Product yield for the reaction = 65%.

Liberation of **Q**(OTf) from **1q**(OTf) under high temperature

A mixture of **1q**(OTf) (0.074 mmol) and 2.5 equivalent of CF₃SO₃H in CH₃CN (5 mL) were refluxed in chlorobenzene for 1.5 hr, during which the colour of the reaction mixture changed from pale yellow to colourless. Upon cooling to room temperature, the reaction mixture was neutralized by NaHCO₃ solution (0.1M). The solvent was then removed via distillation under negative pressure. The solid residue was dissolved in CH₂Cl₂ for a flash neutral alumina column chromatography. The product **Q** was eluted with 100% (CH₃)₂CO. Analytically pure colourless crystals were obtained by recrystallization of the precipitates (via layering of *n*-hexane onto a CH₂Cl₂ solution of the compounds). Isolated yield for **Q** = 11%.

Complex 1q(OTf). Yield: 44%. Anal. Calcd for C₆₆H₅₄SF₃O₃NP₄Ru: C, 64.81; H, 4.45; N, 1.15. Found: C, 64.82; H, 4.44; N, 1.15. ¹H{³¹P} NMR (600 MHz, (CD₃)₂CO): δ 4.80–4.90, 5.22–5.39 (m, 4H, 2 CH₂ on dppm), 6.63–6.64 (m, 1H, H_a), 6.77 (s, 1H, H_e), 7.11 (m, 1H, H_c), 7.16–7.18 (m, 1H, H_b), 7.26 (s, 1H, H_d), 7.41–7.44 (m, 2H, H_g & H_i), 7.52–7.55 (m, 1H, H_h), 7.64–7.65 (m, 2H, H_f & H_j), 6.76–6.77, 6.81–6.82, 6.84–6.87, 6.89–6.92, 7.04–7.18, 7.29–7.32, 7.36–7.39, 7.41–7.58, 7.64–7.65, 7.71–7.72 (m, 40H, protons of 4 Ph rings on dppm). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): δ 47.22, 47.05 (CH₂ on dppm), 112.64 (C_d), 115.45 (C_b & C_c), 126.70 (C_e), 127.38 (C_f, C_h & C_j), 128.11 (C_a), 131.77 (C_g & C_i), 133.94 (C_v), 139.79 (C_{iii}), 141.40 (C_{iv}), 172.73 (C_i & C_{ii}), 128.11, 128.82, 128.99, 129.34, 129.52, 129.69, 129.87, 130.22, 130.40, 130.57, 131.28, 131.80, 132.16, 133.39, 133.74, 137.43, 138.31 (48C of 4 Ph rings on dppm). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -8.19–(-7.39), -1.1652–(-0.7526) (m, 4P on dppm). ESI-MS: m/z 1074.4 [**1q**]⁺.

Complex 1f(OTf)₂. Yield: 64%. Anal. Calcd for C₆₇H₅₇S₂F₆O₇NP₄Ru: C, 57.84; H, 4.13; N, 1.01. Found: C, 57.83; H, 4.14; N, 1.00. Isomeric form A: ¹H{³¹P} NMR (600 MHz, (CD₃)₂CO): δ 4.37–4.40, 4.65–4.68, 4.77–4.80, 5.01–5.03 (m, 4H, 2 CH₂ on dppm), 1.89 (s, 3H, H_e), 6.23–6.25 (m, 2H, H_f & H_j), 6.79 (m, 1H, H_b), 6.88–6.91 (m, 1H, H_g/H_i), 6.98–6.99 (m, 1H, H_a), 7.57–7.59 (m, 1H, H_c), 7.64 (m, 1H, H_g/H_i), 8.08–8.09 (m, 1H, H_d), 8.35–8.39 (m, 1H, H_h), 11.9707 (s, 1H, H_α), 8.08–8.09, 7.67–7.71, 7.57–7.60, 7.22–7.25, 6.89–6.91, 6.23–6.25, 7.52–7.57, 7.43–7.50, 7.22–7.25, 7.12–7.15, 7.05–7.07, 6.73–6.75, 6.64–6.65, 7.84–7.85, 7.52–7.57, 7.43–7.47, 7.33–7.37, 6.96–7.01, 7.64–7.67, 6.38–6.39, (m, 40H, protons of 4 Ph rings on dppm). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): δ 45.23, 42.64 (CH₂ on dppm), 21.12 (C_e), 126.44 (C_g/C_i), 127.57 (C_a), 129.51 (C_g/C_i), 129.67 (C_c), 130.00 (C_b), 130.48 (C_f & C_j), 131.00 (C_{iv}), 134.65(C_{iii}), 134.85 (C_d), 142.44 (C_i), 156.30 (C_{ii}), 146.66 (C_h), 195.23 (C_α), 134.85, 130.32, 131.78, 129.84, 129.51, 130.48, 132.10, 129.67, 130.00, 131.94, 129.35, 129.78, 131.45, 130.97, 132.42, 132.26, 132.59, 137.12 (48C of 4 Ph rings on dppm). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -26.55–(-26.25), -12.33–(-11.12), 1.44–1.81, 2.73–3.85 (m, 4P on dppm). Isomeric form B: ¹H{³¹P} NMR (600 MHz, (CD₃)₂CO): δ 4.21–4.24, 4.49–4.51, 4.30–4.32, 5.04–5.07 (m, 4H, 2 CH₂ on dppm), 1.89 (s, 3H, H_e), 6.86–6.88 (m, 1H, H_a), 7.12–7.13 (m, 2H, H_f & H_j), 7.442 (m, 1H, H_b), 7.48 (m, 1H, H_c), 7.57–7.60 (m, 2H, H_g & H_i), 7.99–8.01 (m, 1H, H_d), 8.35–8.39 (m, 1H, H_h), 11.51 (s, 1H, H_α), 7.99–8.02, 7.57–7.60, 7.44–7.50, 7.35–7.38, 6.99–7.06, 6.32–6.33, 7.71–7.74, 7.35–7.38, 7.22–7.25, 7.64–7.74, 7.22, 6.96–7.03, 6.80–6.83, 7.36–7.38, 7.05–7.07, 6.64–6.65 (m, 40H, protons of 4 Ph rings on dppm). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): δ 42.96 (CH₂ on dppm), 21.12 (C_e), 126.12 (C_g & C_i), 127.73 (C_a), 129.35 (C_f & C_j), 130.00 (C_b), 132.10 (C_c & C_d), 134.41 (C_{iii}), 135.38 (C_{iv}), 140.49(C_i), 146.66 (C_h), 156.06 (C_{ii}), 196.44 (C_α), 134.20, 129.51, 125.95, 130.00, 132.75, 132.26, 130.64, 127.57, 130.32, 131.78, 130.16, 132.59, 134.69, 127.41, 137.12, 130.97 (48C of 4 Ph rings on dppm). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -23.70–(-23.41), -18.04–(-16.80), -1.42–(-0.30), 3.12–3.38 (m, 4P on dppm). ESI-MS: m/z 546.8 [1f]²⁺.

Complex 2q(OTf). Yield: 58%. Anal. Calcd for C₆₆H₅₄SF₃O₃NP₄Os: C, 60.41; H, 4.15; N, 1.07. Found: C, 60.40; H, 4.15; N, 1.08. ¹H{³¹P} NMR (600 MHz, (CD₃)₂CO): δ 5.26–5.29, 5.36–5.39, 6.07–6.09, 6.21–6.23 (m, 4H, 2 CH₂ on dppm), 6.61–6.62 (m, 1H, H_a), 6.77 (s, 1H, H_e), 7.18–7.20 (m, 1H, H_b), 7.27–7.28 (m, 1H, H_c), 7.40–7.43 (m, 1H, H_h), 7.42 (s, 1H, H_d), 7.45–7.475 (H_g & H_i), 7.72–7.74 (H_f & H_j), 6.1–6.62, 7.04–7.05, 7.06–7.09, 7.41–7.43, 7.48–7.75, 6.68–6.69, 6.83–6.85, 7.41–7.43, 7.72–7.74, 6.74–6.77, 6.91–6.94, 7.05–7.08, 7.39–7.40, 7.41–7.42, 7.72–7.74 (m, 40H, protons of 4 Ph rings on dppm). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): δ 52.78, 52.86 (CH₂ on dppm), 111.25 (C_d), 114.23 (C_c), 123.73 (C_a), 125.14 (C_a), 131.86 (C_g & C_i), 132.03 (C_h), 132.91 ((C_g & C_i), 133.23 (C_b), 138.33 (C_{iii}), 139.51 (C_v), 142.74 (C_{iv}), 151.57 (C_i), 151.86 (C_{ii}), 125.14, 130.24, 131.82, 133.23, 131.12, 131.47, 132.87, 128.83, 130.41, 132.45, 130.98, 129.36, 129.71, 129.01, 128.30, 123.73, 135.98, 133.62 (48C of 4 Ph rings on dppm). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -52.49–(-52.29), -48.45–(-47.32), -51.91–(-51.71), -50.11–(-48.96), (m, 4P on dppm). ESI-MS: m/z 1164.8 [2q]⁺.


Complex 2f(OTf)₂. Yield: 72%. Anal. Calcd for C₆₇H₅₇S₂F₆O₇NP₄Os: C, 54.36; H, 3.88; N, 0.95. Found: C, 54.36; H, 3.87; N, 0.94. Isomeric form A: ¹H{³¹P} NMR (600 MHz, (CD₃)₂CO): δ 4.34–4.37, 5.55–5.57 (m, 4H, 2 CH₂ on dppm), 1.78 (s, 3H, H_e), 6.44–6.45 (m, 1H, H_f/H_j), 6.77–6.78 (m, 1H, H_d), 7.40–7.41 (m, 1H, H_a), 7.70 (m, 1H, H_b), 7.70–7.73 (m, 1H, H_g/H_i), 7.74–7.77 (m, 1H, H_g/H_i), 7.79–7.80 (m, 1H, H_f/H_j), 7.86–7.90 (m, 1H, H_c), 8.43–8.45 (m, 1H, H_h), 12.40 (s, 1H, H_α), 8.08–8.10, 7.63–7.69, 7.53–7.58, 7.32–7.34, 6.99–7.04, 6.30–4.32, 7.48–7.51, 7.38–7.41, 7.18–7.22, 7.51–7.58, 7.32–7.36, 7.01–7.04, 6.41–6.43, 7.79–7.80, 7.41–7.46, 7.34–7.37, 6.99–7.00 (m, 40H, protons of 4 Ph rings on dppm). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): δ 48.04, 49.01 (CH₂ on dppm), 21.48 (C_e), 122.0897 (C_d), 126.92 (C_g/C_i), 128.69 (C_b), 128.85 (C_g/C_i), 130.14 (C_c), 130.46 (C_a & C_f/C_j), 132.23 (C_f/C_j), 135.71 (C_{iii} & C_{iv}), 145.42(C_i), 147.04 (C_h), 156.89 (C_{ii}), 196.01 (C_α), 134.16, 132.23, 129.49, 131.75, 130.14, 129.82, 130.30, 130.46, 132.71, 132.07, 130.94, 129.66, 125.79 (48C of 4 Ph rings on dppm). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -57.29–(-57.08), -50.95–(-49.93), -54.45–(-54.25), -47.08–(-46.06) (m, 4P on dppm). Isomeric form B: ¹H{³¹P} NMR (600 MHz, (CD₃)₂CO): δ 4.93–4.96, 5.52–5.57, 4.34–4.40, 6.03–6.06 (m, 4H, 2 CH₂ on dppm), 2.02 (s, 3H, H_e), 6.81–6.82 (m, 1H, H_d), 7.41–7.44 (m, 1H, H_g/H_i), 7.50–7.51 (m, 1H, H_a), 7.55 (m, 1H, H_f/H_j), 7.70–7.73 (m, 1H, H_b), 7.79–7.80 (m, 1H, H_f/H_j), 7.86–7.90 (m, 1H, H_c), 8.08–8.11 (m, 1H, H_g/H_i), 8.35–8.38 (m, 1H, H_h), 11.93 (s, 1H, H_α), 8.18–8.19, 7.78, 7.64–7.69, 7.17–7.22, 6.22–6.23, 6.03–6.06, 7.38–7.58, 7.11–7.17, 6.72–6.74, 7.70–7.73, 6.99–7.01, 6.81–6.82, 7.62–7.63, 7.53–7.56, 7.41–7.45, 7.11–7.15 (m, 40H, protons of 4 Ph rings on dppm). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): δ 48.04, 49.81 (CH₂ on dppm), 21.16 (C_e), 122.57 (C_d), 130.14 (C_c & C_f/C_j), 131.43 (C_g/C_i), 132.07 (C_a), 132.23 (C_f/C_j), 132.87 (C_b), 134.16 (C_g/C_i), 135.71(C_{iii} & C_{iv}), 143.65 (C_i), 146.88 (C_h), 156.30 (C_{ii}), 197.48 (C_α), 134.97, 132.23, 129.49, 129.82, 129.33, 130.62, 130.14, 131.75, 129.66, 131.27, 130.46, 132.71, 131.91, 133.36, 130.94, 125.79, 131.59 (48C of 4 Ph rings on dppm). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -61.25–(-61.02), -37.42–(-36.47), -52.63–(-52.42), -40.34–(-39.37) (m, 4P on dppm). ESI-MS: m/z 602.8 [2f]²⁺.

Complex 2v(OTf). Yield: 62%. Anal. Calcd for C₆₆H₅₄SF₃BrClO₃NP₄Os: C, 55.52; H, 3.81; N, 0.98. Found: C, 55.53; H, 3.81; N, 0.98. ¹H{³¹P} NMR (600 MHz, CD₂Cl₂), *E*- & *Z*-form in *cis*-configuration: δ 5.97, 6.65 (s, 1H, H_a), 6.50, 6.52 (s, 1H, H_b), 7.33–7.35, 7.35–7.37, (m, 1H, H_d), 7.92–7.93, 8.16–8.17 (m, 1H, H_c), 10.01–10.03, 10.06–10.08 (m, 1H, H_e). ¹³C{¹H} NMR (150 MHz, (CD₃)₂CO): the metalated carbon cannot be resolved, 122.15, 130.42 (C_b), 126.90, 127.43 (C_a), 127.95 (C_d), 131.47, 132.70 (C_c), 122.68 (C_e). ³¹P{¹H} NMR (162 MHz, (CD₃)₂CO): δ -65.06–(-63.59), -64.62–(-63.13), -61.32–(-59.96), -59.62–(-58.24), -54.23–(-54.05), -53.62–(-53.38), -53.10–(-52.38) (m, 4P on dppm). ESI-MS: m/z 1278.6 [2v]⁺.


Complex 3(OTf). Yield: 42%. Anal. Calcd for $C_{36}H_{26}SF_3O_3N_5Ru$: C, 56.39; H, 3.42; N, 9.13. Found: C, 56.40; H, 3.41; N, 9.14. 1H NMR (600 MHz, $CDCl_3$): δ 6.29 (m, 1H, H_j), 6.74–6.76 (m, 1H, H_n), 6.83–6.85 (m, 1H, H_i), 7.13 (s, 1H, H_a), 7.16–7.19 (m, 1H, H_c), 7.36–7.39 (m, 1H, H_d), 7.63–7.65 (m, 1H, H_e), 7.71 (s, 1H, H_f), 7.82–7.83 (m, 1H, H_g), 8.18–8.19 (m, 1H, H_b), 8.35–8.36 (m, 1H, H_1), 7.90–7.93 (m, 1H, H_2), 7.42–7.44 (m, 1H, H_3), 7.75 (m, 1H, H_4), 8.17–8.18 (m, 2H, H_5 & H_9), 7.02–7.03 (m, 1H, H_6), 7.50–7.53 (m, 1H, H_7), 8.05–8.06 (m, 1H, H_8), 7.74–7.75 (m, 2H, H_{10} & H_{12}), 7.20–7.23 (m, 1H, H_{11}), 8.19–8.21 (m, 2H, H_{13} & H_{16}), 6.99–7.02 (m, 1H, H_{14}/H_{15}), 7.59–7.62 (m, 1H, H_{14}/H_{15}). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 108.66 (C_f), 119.21 (C_c), 121.85 (C_h), 123.60 (C_g), 125.61 (C_j & C_v), 125.71 (C_e), 128.00 (C_i & C_{IV}), 129.23 (C_d), 135.74 (C_a), 139.94 (C_{III}), 154.20 (C_b), 169.91 (C_l), C_{II} cannot be resolved, 123.08 (C_1), 135.21 (C_2), 127.47 (C_3), 133.28 (C_4), 121.85 (C_5), 125.36 (C_6), 131.69 (C_7), 122.20 (C_8), 121.85 (C_9), 133.28 (C_{10} & C_{12}), 125.71 (C_{11}), 122.90 (C_{13} & C_{16}), 125.36 (C_{14}/C_{15}), 132.75 (C_{14}/C_{15}), 154.92 (C_{VI}), 156.44 (C_{VII}), 157.31 (C_{VIII} & C_{IX}). ESI-MS: m/z 618.2 [3] $^+$.

Ligand L1. Yield: 62%. Anal. Calcd for $C_{15}H_{13}NO$: C, 80.69; H, 5.87; N, 6.27. Found: C, 80.69; H, 5.87; N, 6.27. 1H NMR (600 MHz, $CDCl_3$): δ 2.44 (s, 1H, H_k), 3.23–3.25, 3.32–3.34 (m, 2H, H_e), *OH* cannot be resolved, 7.13–7.14 (d, 1H, H_d), 7.20–7.22 (m, 1H, H_b), 7.28–7.31 (m, 1H, H_n), 7.37–7.39 (m, 2H, H_g & H_i), 7.63–7.65 (m, 1H, H_o), 7.75–7.77 (m, 2H, H_f & H_j), 8.52–8.52 (m, 1H, H_a). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 50.69 (C_e), 72.47 (C_{II}), 73.13 (C_k), 86.52 (C_{IV}), 122.20 (C_b), 124.54 (C_d), 125.41 (C_f & C_j), 127.63 (C_n), 128.20 (C_g & C_i), 137.00 (C_c), 144.17 (C_{III}), 148.16 (C_a), 158.37 (C_l).

Ligand L2. Yield: 72%. Anal. Calcd for $C_{15}H_{12}NOBr$: C, 59.62; H, 4.00; N, 4.64. Found: C, 59.63; H, 4.00; N, 4.64. 1H NMR (600 MHz, $CDCl_3$): δ 2.49 (s, 1H, H_j), 3.19–3.21, 3.30–3.32 (m, 2H, H_d), 6.10 (br, 1H, *OH*), 7.12–7.13 (d, 1H, H_c), 7.29–7.32 (m, 1H, H_g), 7.37–7.39 (m, 2H, H_f & H_n), 7.41–7.42 (m, 1H, H_a), 7.50–7.52 (s, 1H, H_a), 7.71–7.73 (m, 2H, H_e & H_i). $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$): δ 51.12 (C_d), 72.55 (C_{III}), 74.82 (C_j), 86.01 (C_V), 123.35 (C_c), 125.30 (C_e & C_i), 126.91 (C_a), 128.05 (C_g), 128.21 (C_f & C_n), 139.37 (C_b), 140.73 (C_{II}), 143.77 (C_{IV}), 159.84 (C_l).



Scheme S1: Synthesis of Os–vinylidene complex **2v**.



Scheme S2: Previous work on the isolation of Os–indolizone and phosphonium-ring-fused osmafuran complexes.⁵

X-Ray Crystallography

X-ray diffraction data were collected on a Xcalibur, Sapphire3, Gemini ultra, template-Cu, Bruker APEX-II CCD, CCD area detector diffractometer with Cu K α radiations. Using Olex2,⁶ the structures of **1q**(ClO₄)-CH₂Cl₂, [**1f**(CF₃SO₃)₂]₂·1.5Et₂O·1.5H₂O, [**2f**(CF₃SO₃)₂]₂·Et₂O, **2v**(OTf)-CH₂Cl₂ and **Q**(OTf) were solved with the ShelXT⁷ structure solution program using Intrinsic Phasing, **2q**(ClO₄)-CH₂Cl₂ with the ShelXS⁸ structure solution program using Structure Expansion. Refinements were performed with the ShelXL⁹ refinement package using Least Squares minimization.

3(ClO₄)-H₂O with the olex2.solve⁷ structure solution program using Charge Flipping. Refinements were performed with the olex2.refine⁹ refinement package using Levenberg-Marquardt minimisation.

All non-hydrogen atoms were refined anisotropically, except some solvent molecules CH₂Cl₂ were refined isotropically. CCDC 2001062–2001068 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre.

1q(ClO₄)-CH₂Cl₂: Single crystals of **1q**(ClO₄)-CH₂Cl₂ were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of **1q**(ClO₄).

Crystal Data for **1q**(ClO₄)-CH₂Cl₂ (C₆₆H₅₆Cl₃NO₄P₄Ru; *M* = 1258.41 g/mol): monoclinic, space group *P*2₁ (no. 4), *a* = 11.6796(2) Å, *b* = 19.9722(3) Å, *c* = 13.1880(2) Å, β = 104.7930(10)°, *V* = 2974.36(8) Å³, *Z* = 2, *T* = 223.4(8) K, μ (Cu K α) = 4.781 mm⁻¹, *D*_{calc} = 1.405 g/cm³, 13158 reflections measured (8.226° ≤ 2 θ ≤ 143.71°), 8289 unique (*R*_{int} = 0.0272, *R*_{sigma} 0.0391) which were used in all calculations. The final *R*₁ was 0.0305 (*I* > 2 σ (*I*)) and *wR*₂ was 0.0788 (all data). (CCDC 2001062)

[**1f**(CF₃SO₃)₂]₂·1.5Et₂O·1.5H₂O: Single crystals of [**1f**(CF₃SO₃)₂]₂·1.5Et₂O·1.5H₂O were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of [**1f**(CF₃SO₃)₂]₂.

Crystal Data for [**1f**(CF₃SO₃)₂]₂·1.5Et₂O·1.5H₂O (C₇₀H₆₆F₆NO_{8.50}P₄RuS₂; *M* = 1460.30 g/mol): monoclinic, space group *P*2₁/*n* (no. 14), *a* = 22.9780(8) Å, *b* = 16.4419(6) Å, *c* = 36.9317(13) Å, β = 104.0000(10)°, *V* = 13538.4(8) Å³, *Z* = 8, *T* = 173(2) K, μ (Cu K α) = 3.962 mm⁻¹, *D*_{calc} = 1.433 g/cm³, 203671 reflections measured (5.15° ≤ 2 θ ≤ 149.296°), 27634 unique (*R*_{int} = 0.0598, *R*_{sigma} 0.0365) which were used in all calculations. The final *R*₁ was 0.0939 (*I* > 2 σ (*I*)) and *wR*₂ was 0.2635 (all data). (CCDC 2001065)

2q(ClO₄)-CH₂Cl₂: Single crystals of **2q**(ClO₄)-CH₂Cl₂ were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of **2a**(ClO₄).

Crystal Data for **2q**(ClO₄)-CH₂Cl₂ (C₆₆H₅₆Cl₃NO₄OsP₄; *M* = 1347.54 g/mol): monoclinic, space group *P*2₁ (no. 4), *a* = 11.6240(2) Å, *b* = 19.9252(2) Å, *c* = 13.1753(2) Å, β = 104.8180(10)°, *V* = 2950.05(8) Å³, *Z* = 2, *T* = 173.00(14) K, μ (Cu K α) = 6.752 mm⁻¹, *D*_{calc} = 1.517 g/cm³, 11468 reflections measured (6.94° ≤ 2 θ ≤ 136.474°), 7826 unique (*R*_{int} = 0.0240, *R*_{sigma} = 0.0341) which were used in all calculations. The final *R*₁ was 0.0255 (*I* > 2 σ (*I*)) and *wR*₂ was 0.0663 (all data). (CCDC 2001063)

[**2f**(CF₃SO₃)₂]₂·Et₂O: Single crystals of [**2f**(CF₃SO₃)₂]₂·Et₂O were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of [**2f**(CF₃SO₃)₂]₂.

Crystal Data for [**2f**(CF₃SO₃)₂]₂·Et₂O (C₆₉H₆₂F₆NO_{7.50}OsP₄S₂; *M* = 1517.39 g/mol): monoclinic, space group *P*2₁/*n* (no. 14), *a* = 23.0620(5) Å, *b* = 16.4101(4) Å, *c* = 36.9903(9) Å, β = 104.0160(10)°, *V* = 13582.2(6) Å³, *Z* = 8, *T* = 213(2) K, μ (Cu K α) = 5.604 mm⁻¹, *D*_{calc} = 1.484 g/cm³, 161466 reflections measured (5.136° ≤ 2 θ ≤ 149.164°), 27913 unique (*R*_{int} = 0.1004, *R*_{sigma} = 0.0704) which were used in all calculations. The final *R*₁ was 0.0801 (*I* > 2 σ (*I*)) and *wR*₂ was 0.2526 (all data). (CCDC 2001066)

2v(OTf)-CH₂Cl₂: Single crystals of **2v**(OTf)-CH₂Cl₂ were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of **2v**(OTf).

Crystal Data for **2v**(OTf)-CH₂Cl₂ (C₆₇H₅₆BrCl₃F₃NO₃OsP₄S; *M* = 1512.52 g/mol): triclinic, space group *P*-1 (no. 2), *a* = 13.0222(4) Å, *b* = 14.4045(5) Å, *c* = 19.6691(6) Å, α = 79.1010(10)°, β = 71.4600(10)°, γ = 85.6210(10)°, *V* = 3434.40(19) Å³, *Z* = 2, *T* = 173(2) K, μ (Cu K α) = 2.730 mm⁻¹, *D*_{calc} = 1.463 g/cm³, 37106 reflections measured (5° ≤ 2 θ ≤ 52.07°), 13338 unique (*R*_{int} = 0.0459, *R*_{sigma} = 0.0517) which were used in all calculations. The final *R*₁ was 0.0399 (*I* > 2 σ (*I*)) and *wR*₂ was 0.1036 (all data). (CCDC 2001068)

3(ClO₄)-H₂O: Single crystals of **3**(ClO₄)-H₂O were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of **3**(ClO₄).

Crystal Data for **3**(ClO₄)-H₂O (C₃₅H₂₈ClN₅O₅Ru; *M* = 735.161 g/mol): monoclinic, space group *P*2₁/*c* (no. 14), *a* = 9.9119(1) Å, *b* = 14.4815(2) Å, *c* = 21.988(3) Å, β = 97.114(1)°, *V* = 3131.86(7) Å³, *Z* = 4, *T* = 173.00(14) K, μ (Cu K α) = 5.274 mm⁻¹, *D*_{calc} = 1.559 g/cm³, 12177 reflections measured (7.32° ≤ 2 θ ≤ 136.48°), 5727 unique (*R*_{int} = 0.0263, *R*_{sigma} = 0.0291) which were used in all calculations. The final *R*₁ was 0.0378 (*I* > 2 σ (*I*)) and *wR*₂ was 0.0999 (all data). (CCDC 2001064)

Q(OTf): Single crystals of **Q**(OTf) were obtained by layering of *n*-hexane onto a CH₂Cl₂ solution of **Q**(OTf).

Crystal Data for **Q**(OTf) (C₁₆H₁₂F₃NO₃S; *M* = 355.33 g/mol): orthorhombic, space group *P*na2₁ (no. 33), *a* = 13.8910(4) Å, *b* = 16.2450(4) Å, *c* = 6.9806(2) Å, *V* = 1575.24(7) Å³, *Z* = 4, *T* = 173.15 K, μ (Cu K α) = 2.284 mm⁻¹, *D*_{calc} = 1.498 g/cm³, 16540 reflections measured (8.376° ≤ 2 θ ≤ 148.99°), 3107 unique (*R*_{int} = 0.0553, *R*_{sigma} 0.0498) which were used in all calculations. The final *R*₁ was 0.0362 (*I* > 2 σ (*I*)) and *wR*₂ was 0.0955 (all data). (CCDC 2001067)




Figure S3. Perspective view of monocation **2v** as represented by 50% probability ellipsoids (hydrogen atoms are omitted and phenyl rings on dppm are represented by gray sticks for clarity).

Table S1. Selected Bond Lengths (Å) and Angles (deg) for **1q**(ClO₄)·CH₂Cl₂, **2q**(ClO₄)·CH₂Cl₂ and **Q**(OTf)

Complex	1q (ClO ₄)·CH ₂ Cl ₂	2q (ClO ₄)·CH ₂ Cl ₂	Q (OTf)
M–C1	2.087(4)	2.100(5)	-
M–C9	2.075(4)	2.085(5)	-
C1–N1	1.392(5)	1.380(7)	1.381(3)
C9–N1	1.393(5)	1.395(6)	1.382(3)
∠C1–M–C9	64.6(2)	63.7(2)	-
∠M–C1–N1	94.5(2)	95.4(3)	-
∠M–C9–N1	95.0(2)	95.6(3)	-
∠C1–N1–C9	105.9(3)	105.4(4)	119.6(2)
∠P1–M–P2	71.0(1)	70.4(1)	-
∠P3–M–P4	71.0(1)	70.4(1)	-

Table S2. Selected Bond Lengths (Å) and Angles (deg) for $[\mathbf{1f}(\text{CF}_3\text{SO}_3)_2]_2 \cdot 1.5\text{Et}_2\text{O} \cdot 1.5\text{H}_2\text{O}$ and $[\mathbf{2f}(\text{CF}_3\text{SO}_3)_2]_2 \cdot \text{Et}_2\text{O}$

Complex	$[\mathbf{1f}(\text{CF}_3\text{SO}_3)_2]_2 \cdot 1.5\text{Et}_2\text{O} \cdot 1.5\text{H}_2\text{O}^{[a]}$	$[\mathbf{2f}(\text{CF}_3\text{SO}_3)_2]_2 \cdot \text{Et}_2\text{O}^{[a]}$
M–C1	2.038(7), 2.016(7)	2.032(8), 2.034(10)
M–O1	2.140(5), 2.168(5)	2.168(7), 2.141(6)
C1–C2	1.372(11), 1.369(10)	1.360(13), 1.351(14)
C2–C3	1.424(12), 1.409(10)	1.429(14), 1.427(15)
C3–O1	1.274(10), 1.284(9)	1.274(11), 1.276(12)
C2–N1	1.467(10), 1.472(9)	1.457(11), 1.459(13)
$\angle\text{C1–M–O1}$	76.3(3), 76.1(2)	75.2(3), 75.5(4)

[a] The crystal contains two crystallographically independent cations in the asymmetric unit; structural data are listed in the order of M(1) moiety and then M(2) moiety.

Table S3. Selected Bond Lengths (Å) and Angles (deg) for $\mathbf{3}(\text{ClO}_4) \cdot \text{H}_2\text{O}$.

Complex	$\mathbf{3}(\text{ClO}_4) \cdot \text{H}_2\text{O}$
M–C1	2.046(3)
M–C8	2.026(3)
C9–N1	1.389(4)
C10–N1	1.378(5)
$\angle\text{C1–M–C8}$	80.61(12)
$\angle\text{C9–N1–C10}$	119.3(3)

References

- 1 (a) B. P. Sullivan, T. J. Meyer, *Inorg. Chem.* 1982, **21**, 1037; (b) B. P. Sullivan, D. J. Salmon, T. J. Meyer, *Inorg. Chem.* 1978, **17**, 3334.
- 2 J. Schraml, M. Čapka, V. Blechta, *Magn. Reson. Chem.* 1992, **30**, 544.
- 3 S. R. Natarajan, M.-H. Chen, S. T. Heller, R. M. Tynebor, E. M. Crawford, C. Minxiang, H. Kaizheng, J. Dong, B. Hu, W. Hao, S.-H. Chen, *Tetrahedron Lett.* 2006, **47**, 5063.
- 4 B. M. Barchin, J. Valenciano, A. M. Cuadro, J. Alvarez-Builla, J. J. Vaquero, *Org. Lett.* 1999, **1**, 545.
- 5 Y. Aoki, M. Bauer, T. Braun, J. A. Cadge, G. E. Clarke, D. J. Durand, O. Eisenstein, S. Gallarati, M. Greaves, J. Harvey, A. Haynes, U. Hintermair, A. N. Hulme, Y. Ishii, M. Jakoobi, V. R. Jensen, P. Kennepohl, S. Kuwata, A. Lei, G. Lloyd-Jones, J. Love, J. Lynam, S. Macgregor, R. H. Morris, D. Nelson, A. Odom, R. Perutz, M. Reiher, J. Renny, J. Roithova, L. Schafer, S. Scott, P. W. Seavill, J. Slattery, T. Takao, J. Walton, J. D. Wilden, C.-Y. Wong, T. Young, *Faraday Discuss.*, 2019, **220**, 282.
- 6 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *J. Appl. Cryst.* 2009, **42**, 339.
- 7 G. M. Sheldrick, *Acta Cryst.* 2015, **A71**, 3.
- 8 G. M. Sheldrick, *Acta Cryst.* 2008, **A64**, 112.
- 9 L.J. Bourhis, O.V. Dolomanov, R.J. Gildea, J.A.K. Howard, H. Puschmann, *Acta Cryst.* 2015, **A71**, 59.